Study EV-103 Cohort H: Antitumor activity of neoadjuvant treatment with enfortumab vedotin monotherapy in patients (pts) with muscle invasive bladder cancer (MIBC) who are cisplatin-ineligible. Petrylak, D. P., Flaig, T. W., Mar, N., Gourdin, T., Srinivas, S., Rosenberg, J. E., Guseva, M., Yu, Y., Narayanan, S., Hoimes, C. J. LIPPINCOTT WILLIAMS & WILKINS. 2022

View details for DOI 10.1200/JCO.2022.40.6_suppl.435

View details for Web of Science ID 000771008900441